18th International Congress on Thrombosis

Abstracts

Ljubljana, Slovenia, June 20–24, 2004

Guest Editors

Mojca Stegnar, Ljubljana
Mojca Bozic, Ljubljana
Matija Kozak, Ljubljana
Polona Peternel, Ljubljana
Nina Vene, Ljubljana
Drug Dosage

The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
## Contents

### PLENARY LECTURES

<table>
<thead>
<tr>
<th>Title</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>&quot;Resistance&quot; to aspirin and other antiplatelet drugs</td>
<td>PL01</td>
</tr>
<tr>
<td>Cancer and cardiovascular disease: does a common soil exist?</td>
<td>PL02</td>
</tr>
<tr>
<td>Angiogenesis: A link to thrombosis in atherothrombotic disease</td>
<td>PL03</td>
</tr>
<tr>
<td>Antiphospholipid syndrome: association between laboratory tests and clinical practice</td>
<td>PL04</td>
</tr>
<tr>
<td>Coronary heart disease and inflammation - the lessons from therapeutic trials</td>
<td>PL05</td>
</tr>
<tr>
<td>Assessment of endothelial dysfunction: focus on atherothrombotic disease</td>
<td>PL06</td>
</tr>
<tr>
<td>Different locations of atherosclerosis - different risk factors, different therapies?</td>
<td>PL07</td>
</tr>
<tr>
<td>Do platelets trigger atherosclerosis?</td>
<td>PL08</td>
</tr>
</tbody>
</table>

### STATE-OF-THE-ART LECTURES

<table>
<thead>
<tr>
<th>Title</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thrombosis and stroke in neonates, infants and children</td>
<td>SA01</td>
</tr>
<tr>
<td>Metalloproteinases in development and progression of vascular disease</td>
<td>SA02</td>
</tr>
<tr>
<td>Atrial fibrillation and the hypercoagulable state: from basic science to clinical practice</td>
<td>SA03</td>
</tr>
<tr>
<td>Adipose tissue and atherothrombosis</td>
<td>SA04</td>
</tr>
<tr>
<td>Hormone replacement therapy: influence on cardiovascular disease and venous thromboembolism</td>
<td>SA05</td>
</tr>
<tr>
<td>Restenosis; Lessons from therapy</td>
<td>SA06</td>
</tr>
<tr>
<td>Asymptomatic carotid stenosis: natural history and management</td>
<td>SA07</td>
</tr>
</tbody>
</table>

### SYMPOSIA

#### Controversies in diagnosis of VTE

- Extended versus rapid analysis of the leg vein system: A multicenter ultrasound study (The ERASMUS study) - An interim analysis
  
  Bernardi E on behalf of the Erasmus investigators' group
  
<table>
<thead>
<tr>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>SY01</td>
</tr>
</tbody>
</table>

- Can we safely exclude DVT without instrumental testing?
  
  Palareti G
  
<table>
<thead>
<tr>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>SY02</td>
</tr>
</tbody>
</table>

- The role of helical CT in the diagnosis of pulmonary embolism
  
  Huisman M
  
<table>
<thead>
<tr>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>SY03</td>
</tr>
</tbody>
</table>

#### Signalling in platelet adhesion and aggregation

- Receptor cooperation and protein phosphorylation are regulatory mechanisms of platelet recruitment.
  
  Santos M*, Valles J, Moscardo A, Aznar J, Piñon M
  
<table>
<thead>
<tr>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>SY04</td>
</tr>
</tbody>
</table>

- ERK2 activation in collagen platelet aggregation requires cotimulation of Gi-coupled ADP receptor and Gq-coupled TXA2 receptor
  
  Roger S, Mazharian A, Bryckaert M*
  
<table>
<thead>
<tr>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>SY05</td>
</tr>
</tbody>
</table>

- Lysosomal b-N-acetylhexosaminidase is a primer of platelet activation
  
  Rossi R*, Giannini S, Mencarelli S, Falcinelli E, Orlacchio A, Emiliani C, Gresele P
  
<table>
<thead>
<tr>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>SY06</td>
</tr>
</tbody>
</table>

#### Homocysteine

- Gene-gene and gene-environment interactions in mild hyperhomocysteinemia
  
  D'Angelo A*, Mazzola G, Fermo I
  
<table>
<thead>
<tr>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>SY07</td>
</tr>
</tbody>
</table>

- Homocysteine, vitamin B6 and the risk of recurrent venous thromboembolism
  
  Eichinger S*
  
<table>
<thead>
<tr>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>SY08</td>
</tr>
</tbody>
</table>

- Homocysteine lowering by B vitamins and the prevention of deep-vein thrombosis and pulmonary embolism: The VITRO trial
  
  
<table>
<thead>
<tr>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>SY09</td>
</tr>
</tbody>
</table>

- Is hyperhomocysteinemia an important risk factor for cardiovascular disease?
  
  Cattaneo M
  
<table>
<thead>
<tr>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>SY10</td>
</tr>
</tbody>
</table>
How to prevent VTE recurrences

Risk factors for recurrent venous thromboembolism: the role of persistent venous obstruction
Prandoni P

Low-dose warfarin
Palareti G

Duration of warfarin
Agnelli G

TAFl

TAFl at the interface between coagulation and fibrinolysis
Bouma B

TAFl in human ischaemic stroke
Monasterio J

TAFl: Molecular forms of an emerging potential risk factor for thrombotic diseases
Juhan-Vague I*, Frère C, Morange P, Alessi MC

Cancer and VTE

Venous thromboembolism as a 'marker' for cancer: to screen or not to screen
Prins M

Therapy of VTE in different cancer patients
Kakkar AK

Biological and clinical aspects of anticancer effects of antithrombotics
Falanga A

Circulating endothelial cells

Circulating endothelial cells: realities and promises in vascular disorders
Dignat-George F

Circulating endothelial cells and markers of vascular damage: prognostic value
Blann AD

Circulating endothelial cells in vasculitis and transplantation
Woywodt A*, Haller H, Haubitz M

Circulating endothelial cells in preclinical cancer models and in cancer patients

Management of thrombophilia

Genetics of thrombophilia
Castoldi E, Marchetti G, Bernardi F*

Elevated clotting factor levels and venous thrombosis
Bertina R

Management of thrombophilia: who to screen
Baglin T

Thrombocytopenia

New developments in diagnosis and treatment of heparin-induced thrombocytopenia
Lubenow N

Thrombocytopenia as marker of disseminated intravascular coagulation
ten Cate H

The von Willebrand factor-cleaving protease (ADAMTS-13) and the diagnosis of thrombotic thrombocytopenic purpura
Kremer Hovinga J

Factor VIII and von Willebrand factor

What is forthcoming in the treatment of hemophilia and von Willebrand disease
Lee C

The value of factor VIII and von Willebrand factor as risk factors for arterial and venous thrombosis
Martinelli I

ADAMTS13 deficiency: a new mechanism for arterial thrombosis?
Scheiflinger F

D-dimer

Predictive value of D-dimer in recurrent deep venous thrombosis or is it time to tailor anticoagulant therapy according to values of D-dimer?
Palareti G

Clinical usefulness of D-dimer in different groups of patients with suspected venous thromboembolism
Bounameaux H

D-Dimer testing in pregnancy
Eichinger S

Thrombosis in PE

Thrombolysis in submassive pulmonary embolism
Büller HR
**Fibrinolytic system**

The fibrinolytic system and thrombotic tendency  
Kluft C

Fibrin stabilization, fibrin structure and the risk of thrombosis  
Muszbek L*, Bereczky Z, Shemirani A, Katona É

New aspects in thrombosis research: possible role of complement and mast cells as profibrinolytic and anti-thrombotic cells  

**Pharmacogenetics**

Will pharmacogenetics of antithrombotic drugs modify our approach to clinical (mega)trials?  
Iacoviello L*, de Gaetano G

Cytochrome P450 2C9 (CYP2C9) polymorphism and warfarin dose requirement  
Peternel P*, Herman D, Globockar T, Stegnar M, Dolžan V

Antithrombotic efficacy of aspirin and genetic polymorphisms in the hemostatic system  
Musial J*, Szczeklik A, Undas A, Sanak M

**Virchow’s triad revisited**

The blood vessel wall  
Blann AD

Virchow’s triad revisited: blood constituents  
Lip G

Virchow’s triad revisited: abnormal flow  
Lowe GDO

**Prophylactic treatment of VTE**

Assessment of the risk for prophylactic treatment of venous thrombo-embolism in medical patients  
Samama MM*, Gertotziafas G, Horellou M, Elalamy I, Conard J

Assessment of the risk and the prophylaxis of venous thrombo-embolism in surgical patients  
Bergqvist D

Assessment of the risk and prophylactic treatment of venous thrombo-embolism in pregnancy  
Conard J*, Horellou M

Assessment of the risk and prophylactic treatment of venous thrombo-embolism in the elderly  
Couturaud F

**Oral anticoagulant therapy**

Warfarin management in difficult situations  
Palareti G

**Computer assisted anticoagulant therapy**  
Manotti C

**Self adjustment of oral anticoagulant therapy**  
Watzke H

**Dietary interventions**

Mediterranean diet: is all the secret in oil?  
Serra-Majed L

The Mediterranean lecture: wine and thrombosis - from epidemiology to physiology and back  
de Gaetano G

Adherence to Mediterranean diet and coronary heart disease  
Trichopoulou A

**New antithrombotic strategies**

Platelet proteomics: identification of potential therapeutic targets  
Maguire P*, Fitzgerald D

Peptidomimetic inhibitors of thrombin  
Kikelj D

Antithrombotic effects of statins  
Tremoli E*, Colli S, Mussoni L, Sironi L, Banfi C, Camera M

Synthetic Factor Xa inhibitors  
Samama MM*, Gerotziafas G

**The CLAHT symposium**

Role of transfusion programs in stroke prevention in susceptible sickle cell children  

Haemostatic cardiovascular risk factors: differential effects of red wine and diet on healthy young population  
Mezzano D*, Leighton F*

Management of patients with acute venous thromboembolism: Findings from the RIETE Registry  

ORAL COMMUNICATIONS

**Coronary artery disease**

Polymorphisms on thrombospondin genes and premature acute myocardial infarction: a controversy to settle  
Emerging prognostic factors in coronary artery disease

Increased plasma concentration of platelet-derived microparticles in young survivors of myocardial infarction
Michelsen A*, Brodin E, Brosstad F, Hansen J

Gene-gene interaction of the ABCA1 transporter and paraoxonase genes in inherited predisposition to myocardial infarction in young men
Pchelina S*, Sheydina A, Taraskina A, Rodygina T, Schwarzman A

Circulating endothelial cells predict outcomes in patients with acute coronary syndrome: relationship to plasma von Willebrand factor and interleukin-6
Lee W*, Lıp G

High ambulatory pulse pressure is associated with abnormal thrombogenesis and endothelial damage/dysfunction in patients with coronary heart disease
Lee W*, Lıp G

Hematological malignancies
Thrombosis of splanchic veins in patients with silent myeloproliferative disorders
Miljic P*, Sefer D, Sretenovic M, Suvađzic N, Colovic M

A prospective observational study on catheter-related complications in patients with hematological malignancies (CATHEM)

Proteolysis of von Willebrand factor increase in children during the induction therapy for acute lymphoblastic leukemia

Factor XII activity levels in acute leukemia

Alterations of coagulation pathway parameters in children with acute lymphoblastic leukaemia (ALL)

Coordinated dysregulation of cellular receptors, proangiogenic factors and intracellular pathways in acute leukemia

Animal experimental models
Platelets migrate in response to allergen in vivo and in vitro: role of IgE
Pitchford S*, Momi S, Casali L, Gresele P

Successful inhibition of venous thrombus growth after oral administration of BAY 59-7939, a direct Factor Xa inhibitor in rabbits

Increased pulmonary expression of thrombomodulin receptor in rabbits with endothox-induced acute lung injury

PPAR-alpha deficiency does not modify age dependent but prevents high fat diet increase in plasma PAI-I as well as insulin resistance
Mavri A, Bastelica D, Steals B, El Ayachi S, Juhan-Vague I, Alessi MC

Differential expression patterns of proteins in the ischemic myocardium
Jang Y*, Hwang K, Sohn Y, Seung K, Chung KH

VTE prophylaxis
Ximelagatran for the secondary prevention of venous thromboembolism: a complementary follow-up analysis of the THRIVE III Study
Schulman S*, Lundström T, Währlander K, Billing Clasen S, Eriksson H, for the THRIVE III

The development in attitudes towards thromboprophylaxis in Danish surgical departments during a twenty year period
Rasmussen M*, Wegner L, Wille-Jørgens P

A comparison of venous thromboembolism prophylaxis practice patterns in acutely ill medical patients; IMPROVE versus clinical trial populations
Anderson F, Tapson V, Decousus H*, Spyropoulos A, Turpie A, FitzGerald G

Practice variation in USA and Europe for the prevention of venous thromboembolism in hospitalized medical patients: Findings from IMPROVE

Downloaded by: 54.70.40.11 - 11/27/2017 7:02:13 AM
Deep vein thrombosis prophylaxis following arthroscopy, lower limb fractures, and in patients in plaster casts. Results of a survey
Dentali F*, Ageno W, Imberti D

Cancer and thrombosis
Nitric oxide levels and its relevance to C-reactive Protein, CD 40L, TF and TNF-alpha in malignancy associated hypercoagulable state

Platelet activation, coagulation and angiogenesis in breast and prostate carcinoma
Caine G, Lip G, Stonelake P, Ryan P, Blann AD*

Lower APCR correlates with apoptotic activation of CD8+T cells in non-small cell lung cancer

A double-blind placebo-controlled randomized study on enoxaparin for the prevention of upper limb DVT in cancer patients with CVC

Comparison of incidence between thromboembolic events (TEs) and malignancies. An epidemiological retrospective study

Home treatment of cancer patients with deep venous thrombosis

Fibrinolysis
The influence of long-term glycemic control on fibrinolytic activity in type-1 diabetic patients
Seljeflot I*, Larsen J, Dahl-Jørgensen K, Hanssen K, Arnesen H

The effects of rosiglitazone treatment on the fibrinolytic system in patients with type 2 diabetes mellitus
Goldkhen S, Turgut B, Demir M*, Arikan E, Kara M, Turgul A, Vural O

Phospholipids retard fibrinolysis
Kolev K*, Văradi B, Tenekedjiev K, Machovich R, Longstaff C

Impaired fibrinolysis among women with premature Peripheral artery occlusive disease (PAOD)

Plasminogen activator inhibitor-1 gene polymorphism (-675 4G/5G) associated with obesity
Özel D*, Berberoğlu M, Akar E, Akar N

Expression and localization of uPA, PAI-1 and PAI-3 in primary breast cancer

Cardiovascular disease
Serum osteoprotegerin (OPG) levels are decreased in subjects with calcified carotid artery plaques
Mathiesen E*, Vik A, Sveinbjørnsso B, Noto A, Hansen J

Markers of endothelial damage and inflammation correlate with a point-based score for stroke risk in atrial fibrillation
Roldan V, Marin F, Garcia A, Marco P, Sogorb F, Lip G*

Associations of plasma fibrinogen, viscosity, D-dimer and tPA with risk of recurrent strokes in the PROGRESS study
Rumley A, Woodward M, Lowe G*

Plasma angiopoietins 1 and 2, and angiopoietin receptor TIE-2 in congestive heart failure
Blann AD*, Chong AY, Freestone B, Lip G

Increased circulating endothelial cells as an index of endothelial damage in congestive heart failure
Blann AD*, Chong AY, Freestone B, Lip G

Association between obesity, fatty liver and fibrinogen as related to coronary artery disease in sample of the middle-aged urban population
Bogdanov M*, Virc-Bogdanov S

Platelets I
Molecular defects in Tunisian families with Glanzmann thrombasthenia

Activation of platelets exposed to shear stress with smoke extracts of high-nicotine and zero-nicotine cigarettes: the protective effect of nicotine
Jesty J*, Ramachandran J, Bluestein D

Platelets express surface CD40L upon interaction with damaged vessel wall in vivo in humans: effects of aspirin intake
Giannini S*, Rossi R, Guzzetta M, Falconelli E, Orgini G, Gresele P

Ongoing prothrombotic state in patients with hypercholesterolemia: role for soluble CD40 ligand and oxidative stress
Aspirin resistance and prognosis in the setting of non st elevation acute coronary syndromes
Perdios A*, Zairis M, Tsiribis V, Patsourakos N, Lytras A, Fousias S, Tsoukanas K

Application of the cone and plate(let) Analyzer for testing the response to aspirin treatment
Spectre G*, Brill A, Gural A, Turetzy K, Mosseri E, Saviou D, Varon D

**Antiphospholipid syndrome**

Regulation of NF-κB activation in the antiphospholipid syndrome: involvement of ERK1/2 and p38 MAP kinase pathways

Platelet deposition under flow condition is increased in patients with antiphospholipid syndrome who experience thrombotic events
Shenkman B, Levi Y, Tamarin I, Savion N, Shoenfeld Y, Varon D

Laboratory diagnosis of antiphospholipid syndrome: difficulties and possibilities
Makatsaria A*, Khizroeva D, Bitsadze VO, Baimuradova SM

Elevated levels of prothrombin fragment 1+2 in patients with antiphospholipid antibodies but without clinical signs of antiphospholipid syndrome
Ambrožič A*, Božič B, Rozman B

Detection of antiphospholipid antibodies (APAs) in patients with autoimmune and thrombotic diseases
Nagy E*, Sallai K, Gergely P, Bodó I

A survey on diagnosis of lupus anticoagulant among laboratories of the Italian Federation Of Anticoagulation Clinics (FCSA)

**VTE – Clinical aspects I**

Objective assessment of deep vein thrombosis and pulmonary embolism can be deferred without increased risk of thrombosis

Value of D-dimer, for the exclusion of deep venous thrombosis, in the low-moderate and high pre-test probability groups
El Kheir D*, Gerdes V, Büller HR

Residual post treatment ultrasound detected thrombosis is associated with an increased risk of recurrence
Young L, Ockelford P*, Rolfe-Vyson V, McKelvie S, Harper P

The long-term clinical course of acute deep vein thrombosis of upper extremities. A prospective cohort study

Chronic renal failure: thrombotic events and relation with the levels of thrombomodulin, TFPI and von Willebrand factor

Venous thromboembolism and spinal surgery

**Direct thrombin inhibitors**

Efficacy and safety of ximelagatran for prevention of thromboembolism using the EXPRESS regimen across different orthopaedic surgery patient groups

Dabigatran etexilate, new oral direct thrombin inhibitor, in the prevention of thromboembolic events after total hip/knee replacement: BISTRO-2 Study

Influence of time of first dose on the efficacy and safety of postoperative ximelagatran for prevention of thromboembolism after orthopaedic surgery

Timing of initiation of thromboembolism prophylaxis in total hip/knee replacement with dabigatran etexilate, a new oral direct thrombin inhibitor

Ximelagatran/melagatran versus LMWH in major orthopedic surgery: relationship between efficacy and safety and timing of initial administration
Zufferey P, Laporte S, Quenet S, Molliex S, Auboyer C, Decousus H, Mismentti P*

LMWH or ximelagatran versus VKA in the prevention of VTE after major knee surgery: a meta-analysis of randomized controlled trials
Iorio A*, Ferrante F, Nenci G

**Haemophilia**

A familial multi-vitamin K-dependent syndrome associated with compound heterozygosity in the gamma-glutamyl carboxylase gene
Hemophilic arthropathy: A comparison between the findings of magnetic tomography and of simple X-rays
Makris P*, Haritanti A, Fotiadis N, Girtovitis F, Dimitriadis A

Successful treatment of spontaneous intracerebral haemorrhage in a patient with prosthetic mechanical heart valves
Iorio A*, La Torre D, Conti S, Gambelunghe G

Deficient platelet response to collagen: involvement of the glycoprotein VI mediated signaling pathway in two patients
Bellucci S, Huisse M, Boval B, Robert A, Fauvel-Laève F, Jandrot-Perrus M

Reticulated platelets: a reliable parameter to reduce prophylactic platelet transfusion after autologous bone marrow transplantation
Chaoui D, Robert F, Chakroun T, Rio B, Ramdane B, Lecrubier C, Casadevall N, Marie J, Elalamy I*

Metabolic syndrome
Prothrombotic risk in hypertensives with metabolic syndrome

Prognostic role of fibrinogen and D-dimers in diabetic polyvascular disease?
Bosevski M*, Kostoska S, Tosev S, Meskoska S, Borozanov V, Georgievskia L, Peovska I

Do plasma levels of angiogenic factors reflect vitreous levels in patients with proliferative diabetic retinopathy?
Ghosh Y, Reginald A, Banerjee S, Dhintra S, Tyagi A, Lip G*

Plasma vascular endothelial growth factor and angiopoietins in diabetes is related to endothelial damage/dysfunction and atherosclerosis
Lim S*, Blann AD, Lip G

Soluble CD40 Ligand, Interleukin-6 and Tissue Factor in Diabetes and the Effect of Intensive Multi-Factorial Intervention
Lim S*, Blann AD, Lip G

Increased intima-media thickness of carotid arteries in women with previous gestational diabetes mellitus
Janša K*

Platelets II
Determination of platelet derived microparticles in patients with autoimmune thrombocytopenia
Hlusi A, Slavik L*, Krcova V, Pikalova Z

The new mutation in the GP IIIa gene associated with high platelet aggregation is found in Russia
Sirotkina O*, Sheydina A, Vavilova T, Schwarzman A

17 beta-estradiol potentiates thrombin and tromboxane-dependent platelet aggregation and exposition of fibrinogen binding sites on platelet surface
Pietrapiana D*, Moro L, Reineri S, Piranda D, Bordone R, Bertoni A, Torti M, Sinigaglia F

gp91phox-dependent expression of platelet CD40 ligand

Participation of ADP and TXA2 receptors in the signal transduction that regulate platelet recruitment. Effects of erythrocytes
Moscardo A*, Santos M, Valles J, Aznar J, Dasi MA, Piñon M

Influence of oxidatively modified fibrinogen on platelet function
Dyr JE*, Vanickova M, Suttar J

Pregnancy I
Markers of haemostatic activation in pregnant women with deep-vein thrombosis
Božeč M*, Antolič B, Peternel P, Šajina-Stritar B, Stegnar M

Retrospective analysis of thrombophilic parameters in women with adverse pregnancy outcome

Venoous thromboembolism after elective cesarean section
Jacobsen A*, Drolsum A, Kløw N, Dahl G, Qvigstad E, Sandset P

Placental vascular abnormalities in neonatal alloimmune thrombocytopenia (NAIT)
Weir E*, Althaus J, Blakemore K, Askin F, Kickler T*

Rationalising of diagnostic management of pulmonary embolism in pregnancy: fetal radiation exposure in radiologic procedures

Increased titer of antiphospholipid antibodies in women with high risk pregnancy
Hoppensteadt D*, Cunanan J, Oplatek A, Fareed J
Inherited protein S deficiency type I, but not type III is a risk factor for venous, but not arterial thrombosis; a study in 81 families
Brouwer JLP*, Veeger N, van der Schaaf W, Klun-Nelmanns H, van der Meer J

Markers of inflammation, D-dimer and recurrences after a first episode of venous thromboembolism
Cosmi B*, Legnani C, Guazzaloca G, Coccheri S, Palareti G

Success of initiatives to familiarize vascular physicians in Germany with outpatient treatment of deep venous thrombosis
Werner B*, Jürgen D, Horst E G

Cost-effectiveness of bemiparin in the acute and long-term treatment of deep vein thrombosis
Rocha E, Gómez-Outes A*, Martínez-González J*, Kakkar V

Outpatient tinzaparin therapy in 102 patients with pulmonary embolism - final results
Olsson*, Bajc M, Bitzén U, Carlsson MS, Elf J, Jönsson K, Magnusson P, Olsson B, Jonson B

Analysis of predisposing factors and 6 month outcomes of DVT management in 668 patients treated with LMWH(tinzaparin) as outpatients
Rhodes S, Bond S*, Green E

Haplotypes of the EPCR gene, plasma sEPCR levels and the risk of deep venous thrombosis
Uitte de Willinge S*, van Marion V, Rosendaal F, Vos H, de Visser M, Bertina R

Expression and characterization of a new factor V mutation (R1698W) found in combination with FV Leiden
Lunghi B, Scanavini D, Ulazzi L, Busani C, Redaelli R, Tagariello G, Bernardi F*

Genetic markers of inflammation and sensitivity to activated protein C (APC)
González-Ordóñez A*, Macias D, Arias A, Fernández-Carreira JM, Morán M, Peliz M, Martin L

Frequency of cytochrome CYP2C9 polymorphism in Russian Population and it effects in 62 patients treated by warfarin
Vavilova T*, Sirotkina O, Ulitina A, Kadinskaya M, Schwarzman A

TNFRI +36 G/G genotype and the metabolic syndrome both predispose obese women to higher levels of soluble TNFRs, PAI-1 and liver enzymes

Fibrinogen polymorphisms Taq I, Hae III and Bcl I are not major risk factors for deep-vein thrombosis
Božič M*, Teran N, Peterlin B, Stegnar M

Ischemic stroke

Inherited risk factors for ischemic stroke
Sirotkina O*, Tcherkas Y, Elchaninov A, Merkulova A, Chukhlovina M, Denisenko A, Schwarzman A

Inherited prothrombotic risk factors (factor V G1691A, factor II G20210A, MTHFR C677T and platelet polymorphisms) in pediatric ischemic stroke

Congenital thrombophilia in patients with cerebral ischemia and patent foramen ovalis (PFO)

Lipoprotein(a) and C-reactive protein in children with cerebrovascular Events
Zrinski Topić R, Coen D*, Puček M, Miloš M, Leniček-Križa J, Dodig S

Frequency of cytochrome CYP2C9 polymorphism in Russian Population and its effects in 62 patients treated by warfarin
Gasse C*, Hollowell J, Meier C, Troost J, Schneider V, Haefeli W

Drug interactions and risk of acute bleeding leading to hospitalisation or death in patients with chronic atrial fibrillation treated with warfarin

Telemedicine for managing patients on oral anticoagulant therapy

Oral anticoagulant treatment I

Bleeding complications of oral anticoagulation therapy: a prospective audit
Bond S*, Rhodes S, Green E, James R, Taylor M, Rose P, Emmas C

The relationship of D-dimer and residual vein thrombosis as risk factors for recurrent venous thromboembolism after anticoagulation withdrawal
Cosmi B*, Legnani C, Cini M, Guazzaloca G, Palareti G

Drug interactions and risk of acute bleeding leading to hospitalisation or death in patients with chronic atrial fibrillation treated with warfarin
Gasse C*, Hollowell J, Meier C, Troost J, Schneider V, Haefeli W

The effect of vitamin K substitution on anticoagulant treatment
Rombouts E*, Van der Meer F, Rosendaal F

Telemedicine for managing patients on oral anticoagulant therapy

X Pathophysiol Haemost Thromb 2003; 33 (suppl2)
OAT with POC devices and remote computer monitoring in the setting of the Italian NHS: a controlled clinical trial
Paciamiccio E, Ferrante F, Trottini S, Rosafalco M, Duca E, Maria V, Nenci G, Alfonso I*

Postthrombotic syndrome

Below-knee elastic compression stockings for prevention of the post-thrombotic syndrome. A randomized study

Do vena cava filters increase the incidence of postthrombotic syndrome? Results from the eight-year follow-up of the randomised PREPIC trial
Quenet S*, Rivron-Guillot K, Decousus H

Postoperative asymptomatic deep vein thrombosis and the development of postthrombotic syndrome: A systematic review
Wille-Jørgens P*, Jorgensen L

Inter-observer variables in results of compression ultrasonography performed in acutely ill medical patients

Factors predicting long-term venous thrombotic complications after insertion of vena cava filters: results of the randomised PREPIC trial
Buchmuller-Cordier A*, Laporte S, Decousus H

Elastic stockings, hydroxyethylrutosides or both for the treatment of the post-thrombotic syndrome. A pilot randomized study

Pregnancy II

Factor V Leiden, prothrombin G20210A and MTHFR C677T mutations in women with abruptio placenta
Procházká M*, Slavik L, Procházková J, Hrachovec P, Króvá V

Factor V Leiden, FII G20210A, MTHFR C677T, A2756G MTR and 844ins68 CBS gene polymorphisms in atrial fibrillation

Safety and efficacy of nadroparin for the treatment or prophylaxis venous thromboembolism in pregnancy
Barillari G*, Biffoni F, Springolo F, Marchiondi D

APC-NR and PC-NR as markers of prethrombotic changes in pregnancy
Vodnik T*, Vukosavljević D, Ignjatović S, Majkić-Singh N

Monitoring low molecular weight heparin in pregnancy: the timing of the peak measurement
Shiach C*, Johnston T

Patients on oral anticoagulant treatment: anticoagulation clinic vs assistant physician

Efficacy and risk of anticoagulant therapy in 102 patients with thrombosis and cancer

Vitamin K antagonists are less prescribed in outpatients with permanent lone atrial fibrillation: results of a large observational survey in France
Cohen A*, Guenoun M, Le Heuzey J, Mismetti P, Leizorovicz A, for the FALSTAF Study Group

Comparative effects of antiplatelet, anticoagulant or combined therapy in patients with valvular and non-valvular atrial fibrillation

Hyperhomocysteinemia

Regression of severe atherosclerotic lesions after vitamin replacement in hyperhomocysteinemia with multiple heterozigous mutations

Gene polymorphisms (C677T and A1298C MTHFR, A2756G MTR and 844ins68 CBS) in atrial fibrillation

Homocysteine, vitamins and C-reactive protein in the InCHIANTI Study
Absolute risk of venous and arterial thromboembolism associated with mild hyperhomocysteinemia
van de Poel M*, Libourel E, Bank I, Middeldorp S, Hamulyak R, Prins M, Büller HR, van der Meer J

Methionine loading test affects thrombin generation in high risk patients
Domagala TB*, Undas A, Celinka-Lowenhoff M, Rybak M, Szczeklik A

Hyperhomocysteinemia in cancer patients with thrombosis is independent of methylene tetrahydrofolate reductase gene mutation
Cunanan J*, Tobu M, Iqbal O, Demir M, Fareed J, Deitche S

Metalloproteinases
Circulating tissue inhibitor of metalloproteinase-1 elevation correlates with impaired diastolic relaxation in patients with hypertension
Tayebjee M*, Nadar S, MacFadyen R, Lip G

Circulating MMP-9, TIMP-1 and TIMP-2 in gestational hypertension
Tayebjee M*, Karalis I, Nadar S, Beevers DG, MacFadyen R, Lip G

Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension: Relationship to cardiovascular risk and treatment
Tayebjee M*, Nadar S, Blann AD, Beevers DG, MacFadyen R, Lip G

Correlation of protein and mRNA expression of fibrinolytic and matrix metalloproteinase systems in endometriosis

Popliteal arterial aneurysm - the role of proteolytic enzymes
Kozak M*, Štalc J, Tominc U

The roles of serum matrix metalloproteinases in patients with post myocardial infarction to heart failure
Jong G*, Ma T, Kuo S

Heparins
Managed hemostasis “point-of-care” testing in a large hospital: a three-year experience and the assessment of clotting tests

Once-daily LMWH versus UFH for the treatment of acute venous thromboembolism: a non-inferiority meta-analysis

Therapeutic implications of product individuality in commercially available low molecular weight heparins and their generic versions

Evaluation of the effectiveness and safety of bemiparin, a second-generation low-molecular-weight heparin, in several orthopaedic settings

Bemiparin prospective observational study on the prevention of venous thromboembolism in medical patients
Gómez-Outes A, Martínez-González J*, Maeso R, García-Hernández A

Low-molecular-weight heparin causes less heparin-induced antibodies than unfractionated heparin: A prospective study in neurologic patients
Harbrecht U*, Andrea K, Britta B, Peter H, Thomas K, Christoph P

Thrombophilia
Factors I, VII, VIII, IX, X and XI levels and the risk of deep venous thrombosis
Mello T, Machado T, Ozello M, Annichino-Bizzacchi JM*

High factor VIII (FVIII) levels in venous thromboembolism: role of the unbound component of FVIII

The relationship between inherited thrombophilia and residual vein thrombosis as risk factors for recurrent venous thromboembolism
Cosmi B*, Legnani C, Cini M, Guazzaloca G, Palareti G

Retinal vein thrombosis and thrombophilic risk factors

Risk factors for CNS thrombosis in neonates and children
Pergantou H*, Kapsimali Z, Adamtziki E, Platokouki H, Vranou M, Aronis S

Coagulation activation in patients with and without thrombophilia during anticoagulant treatment for venous thrombosis
Vižintin Cuderman T*, Božič M, Peternel P, Stegnar M

TAFI
A new TAFI antigen assay independent of polymorphism 325Thr/Ile and 147 Ala/Thr
Cost H, Grimaux M, Grosley M, Woodhams B*
Influence of the Thrombin Activatable Fibrinolysis Inhibitor (TAFI) Thr325Ile polymorphism on TAFI levels determined with three new assays
Frère C, Aillaud MF, Saut N, Grosley M, Beltran J, Juhun-Vague I, Alessi MC

TAFI levels in patients with acute myocardial infarction treated with thrombolysis

Mediation of fibrinolytic deficit in cancer patients by plasminogen activator inhibitor-1 and thrombin activatable fibrinolytic inhibitor
Florian-Kujawski M*, Hoppensteadt D, Iqbal O, Demir M, Tobu M, Fareed D, Fareed J

Modulation of thrombin activatable fibrinolytic inhibitor (TAFI) by heparins: Variation among normal and patient populations

Does thrombin activatable fibrinolysis inhibitor (TAFI) contribute to hemostatic complications in patients with different types of brain injury?

FEATURED POSTERS

Cardiovascular disease I

Abnormal heart rate variability is associated with platelet activation in stable coronary disease during recovery from myocardial infarction
Hamaad A*, Blann AD, Lip G, MacFadyen R

Abnormalities in heart rate variability is associated with platelet activation in acute ST-elevation myocardial infarction
Hamaad A*, Blann AD, Lip G, MacFadyen R

EPCR 23 bp Insertion in Atherosclerosis and Early MI
Ulus A*, Akar R, Emiroglu O, Ucanok K, Akar E, Akar N

Soluble tissue factor in plasma from patients with acute myocardial infarction is not microvesicle associated
Seljeflot I*, Lyberg T, Arnensen H

The effects of home-based versus hospital-based cardiac rehabilitation on plasma haemostatic markers in patients with coronary heart disease
Lee W*, Jolly K, Lip G

Anticoagulant therapy

Hemostatic markers in patients with chronic atrial fibrillation - relationship to thromboembolic risk
Vene N*, Mavri A, Košmelj K, Stegnar M

Anticoagulation in conventional versus transesophageal echocardiography guided cardioversion of atrial fibrillation
Dokler Glavnik A*, Žohar P*, Gunzek R*, Bervar M*, Marinšek M*, Skrabič Močnik P*

Low molecular weight heparin limits prothrombotic reactions and may shorten in-hospital stay of patients with heart failure
Wachnicka-Truty R*, Birkholz-Golaszewska A, Korzeniowski A, Flasiński J, Görski J

Replacing acenocoumarol with the low molecular weight heparin Tinzaparin sodium in patients undergoing general surgery operations: a pilot study

Oral Anticoagulant Therapy Management In Patient Self-Testing
Testa S*, Alatri A, Morstabilini G

Methods in coagulation

Anti-Xa activity monitoring of the synthetic pentasaccharide Fondaparinux
Van Dreden P*, Fontaine S, Woodhams

The Ecarin Chromogenic Assay (ECA) for quantitative determination of direct thrombin inhibitors-From a routine method to a point-of-care test
Lange U*, Frische I, Olschewski A, Nowak G, Bucha E

Cardiovascular disease II

Dietary habits and their role on the occurrence of coronary artery disease: is the Italian a real Mediterranean-diet?

Oxidative stress—a link between endothelial injury, coagulation activation and atherosclerosis in haemodialysis patients
Pawlak K*, Naumnik B, Brzosko S, Pawlak D, Mysliwiec M
NCX 6550, a nitric oxide (NO)-releasing derivative of pravastatin, exerts antiplatelet and antithrombotic activity
Momi S*, Rossiello M, Caracchini R, Monopoli A, Ongini E, Gresc P, Colucci M

Inhibition of integrin activation and expression in vascular smooth muscle cells
Sohn Y, Pyun W, You W, Jang Y, Seung K, Chung KH

Fibrocytes in atherosclerosis

Platelets
Influence of antiplatelet therapy on platelet-mediated thrombin generation after carotid stenting
Piñon M*, Valles J, Santos M, Lago A, Tembl J, Aznar J, Moscardo A

Role of PECAM-1 in acutely formed platelet thrombi during human microvascular anastomosis
Olsson E*, Sarlomo-Rikala M, Böhling T, Lassila R

Effects of CML Drugs (taxol, rapamycin and glivec) on Platelet Aggregation and on Fibrinogen Binding to Platelets
Tetik S*, Eksioglu-Demiralp E, Yardimci T

The Release of Matrix Metalloproteinase-9 in Human Platelets: Regulation of Platelet Activation in In Vitro and In Vivo Studies
Sheu J*, Shen M, Hsiao G

Is assay of fibrin gel permeability a precise way to determine the effects of acetylsalicylic acid on coagulation?

VTE
Plasma levels of Factor VIII, IX and XI and Risk of Recurrent Venous Thromboembolism

The value of compression ultrasound in diagnosis of asymptomatic deep venous thrombosis in acutely ill medical patients

High incidence of symptomatic chronic thromboembolic pulmonary hypertension after symptomatic pulmonary embolism

Observational study of bemiparin, first dose administered 6 hours after surgery, in hip or knee replacement surgery
Abad JI, Gómez-Outes A, Martinez-González J*, Maeso R, Rocha E
Cancer

Effect of combination anti-angiogenesis therapy on markers of coagulation, platelet activation and angiogenesis in patients with advanced cancer
Caine G, Harris A, Christodoulos K, Lip G, Blann AD

Intrinsic “tenase” and prothrombinase activity of t-lymphoblastoid cells is enhanced by lipid peroxidation
Pickering W*, Gray E, Goodall A, Barrowcliffe T

Upregulation of monocyte chemotactic protein-1 and CD40 ligand in cancer patients and their modulation by subcutaneous enoxaparin
Fareed J*, Tobu M, Demir M, Hoppensteadt D, Deitcher S

Platelet-derived vegf, flt-1, angiopoietin-1 and p-selectin in breast and prostate cancer
Gómez-Outes A, Martinez-González J*, del Campo J, Rocha E*

POSTERS

Cardiovascular disease

Ischaemic cardiopathy and associated risk factors in two elderly women groups of low socio-economic condition

Factors that may influence in the adequate control of arterial hypertension

Coronary heart disease estimation in an elderly population

Prothrombotic risk in white coat hypertensives
Theodossiades G*, Vyssoulis G, Karpanou E, Zervoudaki A, Tsevrenis V, Kokkinos D, Stefanidis C

Pathogenetic role of nitric oxide in thromboembolic complications in patients with chronic heart failure
Mirsamatova G

A comparison between intima-media thickness and coronary artery disease

The effects of incremental shuttle walking on activation of haemostatic and haemorheologic markers in patients with coronary heart disease
Lee W*, Ingram J, Kolly, Lip G

Use of low-molecular-weight-heparin in early cardioversion
Dokler Glavnik A*, Škrabl Močnik F, Žohar P, Bervar M, Marinšek M, Gunzek R

Left ventricular diastolic dysfunction is associated with abnormal haemorheology, thrombogenesis and endothelial damage/dysfunction
Lee W*, Lip G

Plasma vascular endothelial growth factor (VEGF) and the angiopoietin/Tie2 System in proliferative sickle retinopathy
Mohan J, Lip P, Bareford D, Blann AD*, Lip G

Fluid shear stress, blood coagulation and epigenome topography of granulocytes nuclei at atherosclerosis: what is evident?
Tepljakov A

New polymorphism in the first intron of the ABCA1 transporter gene
Sheydina A*, Pchelina S, Demina E, Schwarzman A

Enhanced level of tissue-type plasminogen activator antigen in hypertensive small deep infarcts
Ionova V*, Suslina Z, Maximova M, Tanashian M, Klimovich L

Hyperhomocysteinemia is significant risk factor for cerebral arterial occlusive diseases in North West Russia
Shmeleva V*, Kapustin S, Papayan L

Oral methionine load induces von Willebrand factor changes in women with peripheral occlusive disease
Peutelli P*, Amato S, Bottini F, Minniti G, Cerone R, Molinari A

Analysis of 5 SNPs of the ABCA1 gene in patients with ischemic stroke
Taraskina A, Sheydina A*, Sirotkina O, Elchaninov A, Pchelina S

ASO titer and efficacy of streptokinase in acute myocardial infarction patients
Ostovan M*, Hooshmand S

Lymphocyte platelet adhesion in acute coronary syndrome
Solpaov A*, Govorin A, Gorbunov V, Vitkovsky Y

Different molecules of endothelial origin - master of cytokines network balance: new evidence of lymphocytes functioning at atherosclerosis
Tepljakov A*


Coagulation factors and inhibitors

Protein C as diagnostic marker in early diagnosis of severe intra-abdominal infections Vukosavljević D*, Vodenik T, Majkić-Singh N, Karamarković A

Is factor VII deficiency predisposing to foetal loss? (Study of a large family) Lo Pinto G*, Perroni L, Cusano R, Barabesi M, Costa M, Malatesta V


A proteomic approach for the resolution of vitamin K-dependent proteins Uras F*, Salman Dilgimen A, Uras A

Factor XIII Val34Leu polymorphism as a modulator of resistance to fibrinolysis in subjects treated with aspirin Undas A*, Brožek J, Iwaniec T, Szczeklik A

Factor VII activity and blood coagulation at the site of microvascular injury Brzezinska B, Undas A, Padjas A*, Iwaniec T, Musial J

Role of fibrin in thrombin behavior de Bosch N

Factor XIII level and prevalence of FXIII-A Val34Leu polymorphism in patients with peripheral arterial disease and Raynaud's disease Shemirani A*, Csiki Z, Szomják E, Katona É, Bereczky Z, Muszbek L

Factor XIII subunit B: a protein A-binding protein Kerényi A*, Haramura G, Muszbek L

Effect of short wave frequency electromagnetic radiation on lymphocyte-platelet adhesion and tissue factor expression by leukocytes Nardina I*, Vitkovsky Y

FVIII Levels During Attacks of Familial Mediterranean Fever Akar N*, Ekim M, Gürman C

Successful use of recombinant activated factor VII (rFVIIa) in a patient with severe bleeding during transabdominal retropubic prostatectomy Monteiro C*, Jorreto M, Gonçalves L, Fraga M, Pereira R

Tensile strength of blood clot Savuskin AV*

Blood clot: hydraulic resistance and its changing Savuskin AV*

Erythrocyte desert out the blood clot phenomenon (filtration "back to front") Savuskin AV*

Anticoagulant therapy

Warfarin is superior to Acenocoumarol in the management of patients requiring low doses of oral anticoagulants Cereseetto JM*, Rabinovich O, Stemmelin G, Shanley C, Dubosq C, Gutierrez M, Mendizabal G, Doti C, Vicente M, Bullorsky E

Validation of CoaguChek S on samples of patients on stable oral anticoagulation Laszlo P*

Dental surgery in patients treated with oral anticoagulants Dimova C*, Kostovska S, Dejanova V, Kovacevska I, Andonovska B

Evaluating the interaction of allopurinol with the oral anticoagulants Rodrigues*, Martins R, Viegas E

Reurrence of deep vein thrombosis in a patient with combined thrombophilic disorder, complicated by warfarin-induced liver damage Hirmerová J*, Mecová E, Chudáček Z


Patient relationship to the oral anticoagulant therapy with regard to the age, level of education and duration of treatment Vukelic-Damijani N*, Caser L, Skalamera R, Vujaklija-Stipanovic K


Importance of continuous education in anticoagulated patients Iriarte J*, Longa M, Zorraquín A, Santos M, Vacas M, Narvaez I, Sabino E, Gandarias JM, Saez Y, Saez de Lafuente J
A new approach to identify blood sample collected from hospitalized patients receiving anticoagulant therapy
Katz B, Kirner I*, Eidelman L, Zwang E, Vardimon H, Goncharov I, Mar-Zev F, Deutsch V

Prolonged increase of plasma vitamin K2 concentration by natto (Bacillus subtilis natto) ingestion
Yatagai C, Yanagisawa Y, Ohsugi T, Sumi H*

How does age influence the prescribing of antithrombotic therapy for ambulatory patients with permanent atrial fibrillation?
Leizorovicz A*, Guenoun M, Le Heuzey J, Jeandel C, Mismetti P, Cohen A

Animal experimental models
Surface-expressed mediators on activated platelets are required for pulmonary leukocyte recruitment in a murine model of allergic inflammation
Pitchford S*, Giannini S, Momi S, Casali L, Gresele P

Activated platelets induce APC-resistance in vivo
Leone M, Momi S, Colucci M, Gresele P*

The thrombotic effect of longolamine external application in rabbits
Tamara S, Lidia P, Tamara S, Rosa M, Leonid N, Galina A

Antithrombotic effects of BAY 59-7939, an oral, direct Factor Xa inhibitor, in models of thrombosis and bleeding time in rats and rabbits
Perzborn E*, Buetehorn U, Lampe T, Pernerstorfer J, Pohlmann J, Roehrig S, Schlemmer K, Straub A

Pharmacokinetics of BAY 59-7939 - an oral, direct Factor Xa inhibitor - in rats and dogs

The assessment of MDA and SOD after the administration of Allopurinol in the Ischemia-reperfusion syndrome of the small bowel
Sapalidis K, Makris P*, Girtovitis F, Anestakis D, Deligiannnidis N, Gamvros O

The postoperative inflammatory reaction (IR) in dependence of using different surgical scalpels in experiment
Tatyana S, Ludmila L, Margarita K, Ospan M, Galina A

The formation of stable prethrombotic state is result in an action of different psychostimulators
Tamara S*, Lidiya P, Kira N, Victoria S, Galina A

Cancer and thrombosis
Determination of coagulation inhibitor activity and resistance to activated protein C in non-small cell lung cancer patients (NSCLC)

Angioplasty (ANG) And Anticoagulation (ATC) In Superior Vena Cava Syndrome (SVCS)
Celebrin L*, Carlevaro O, Bluguermann J, Mauro D, Bezares R, Antonio D, Parise F

Chemotherapy-induced activation of haemostasis: the role of D-dimer

Coagulation derangements in oral and maxillofacial surgery in patients with a documented cancer: a follow-up study after surgery
De Lucia D*, Napolitano M, Misso M, Tagliaferri A, De Francesco F, Borriello C, Coella G

Budd Chiari syndrome in patients with myeloproliferative disorders (MPD) and high platelet count: evidence for an endothelial pathology
Randi ML, Luzzatto G, Cella G, Tezza F, Fabris F*

Endothelial cells
Endothelial damage/dysfunction and thrombogenesis in diabetes: positive effects of multifactorial intervention
Lim S*, Blann AD, Lip G

Inhibitory mechanisms of YC-1 and PMC in the induction of iNOS expression by lipoteichoic acid in RAW 264.7 macrophages
Hsiao G*, Huang H, Sheu J

An improved assay for the enumeration of circulating endothelial cells
Woywodt A*, Goldberg C, Scheer J, Regelsberger H, Haller H, Haubitz M

Circulating endothelial cells as a marker of endothelial damage in allogeneic hematopoietic stem-cell transplantation

Assessment of endothelial damage in atherosclerotic vascular disease by quantitative of circulating endothelial cells
Blann AD*, Makin A, Chung N, Silverman S, Lip G

Hemorheology, hemostasis and antiaggregat activity of endothelium in patients with borderline hypertension
Maximova M*, Ionova V, Suszina Z, Tanashian M, Lutova L, Karabasova M
Gene expression profiling of endothelial cells from normal and systemic sclerosis patients

Comparison of platelets’ and endothelium function between diabetics and normal subjects

The evaluation of disfunction of endothelium in patients with hypertensive small deep infarcts
Maximova M*, Suslina Z, Ionova V, Tanashian M

Direct thrombin inhibitors

The influence of melagatran on thrombin generation, comparison with other anticoagulant drugs
Al Dieri R*, Hemker H, Béguin S

Melagatran is efficiently eliminated by hemodialysis in uremic patients
Eriksson UG, Samuelsson O, Attman PO, Lepkowska M, Ohlsson L, Carlsson S, Fager G

No influence of food on the pharmacokinetics, pharmacodynamics, or tolerability of the 36mg oral tablet formulation of ximelagatran
Ersdal E*, Schützer K, Eriksson UG, Lönnerstedt C, Ohlsson L, Wall U

Efficacy and safety of postoperative ximelagatran for prevention of thromboembolism across different orthopaedic surgery patient groups

Effect of the oral, direct Factor Xa inhibitor, BAY 59-7939, on thrombin generation after tissue factor pathway activation
Gerotziafas G*, Depasse F, Chakroun T, Elalamy I, Samama M

Studies on the mechanism of action of BAY 59-7939 - an oral, direct Factor Xa inhibitor

Effects of BAY 59-7939, an innovative, oral, direct Factor Xa inhibitor, on thrombin generation in healthy volunteers

Biochemical and pharmacologic properties of BAY 59-7939, an oral, direct Factor Xa inhibitor

Multiple dose escalation study investigating BAY 59-7939 - an oral, direct Factor Xa inhibitor - in healthy male subjects
Kubitza D*, Becka M, Wensing G, Voith B, Zuehlsdorf M

Single dose escalation study of BAY 59-7939 - an oral, direct Factor Xa inhibitor - in healthy male subjects
Kubitza D*, Becka M, Wensing G, Voith B, Zuehlsdorf M

The oral direct thrombin inhibitor ximelagatran shows bioequivalence when administered as whole or crushed tablets or in solution via nasogastric tube
Schrützer K*, Lönnnerstedt C, Wall U, Ohlsson L, Sarich T, Teng R, Eriksson UG

The pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran when administered with erythromycin
Dorani H*, Schützer K, Sarich T, Wall U, Ohlsson L, Eriksson UG

Lipoproteins and haemostasis

Effect of malondialdehyde modified low density lipoproteins on platelet adhesion
Suttner J*, Otahalova E, Dyr JE, Cermak J

Lipoprotein (a) as a marker of diffuse coronary artery disease in young survivors of myocardial infarction

The effect of the new Russian food supplement “Eiferol” on the hemostasis and lipid metabolism in patients with disease of the liver
Vjacheslav I*, Valentina P, Galina A, Margarita K, Ludmila L

Atorvastatin affects thrombosis/fibrinolysis system during the acute phase of unstable angina
Kotsopoulou M*, Bosinakou E, Tousoulis D, Antoniades C, Fostira E, Pitsavos C, Stefanadis C

Effects of atorvastatin on thrombosis/fibrinolysis system and endothelial function, in patients with heart failure
Kotsopoulou M*, Antoniades C, Tousoulis D, Bosinakou E, Cheimona A, Pitsavos C, Stefanadis C
Fibrinolysis

The t-PA and PAI-1 activities under treatment by thrombolytic and anticoagulant medicaments in patients with acute myocardial infarction
Krasnobryzha I*, Savchuk O

Relationship between global fibrinolytic capacity and cardiovascular risk factors in obese patients
Turgut B, Gulüken S, Demir M*, Uğur-Altun B, Gerendi M, Vuralo O, Turgul A

Tissue plasminogen activator plasma levels is an independent predictor of in-hospital major events in patients with unstable angina

D-dimer promotes endothelial dysfunction in diabetes mellitus
Yevdokimova N*, Lugovskij E, Komisarenko S

Pretreatment PAI-1 levels and streptokinase thrombolysis in Iranian patients with acute MI in spite of negligible antistreptokinase antibodies
Shemirani H*, Tajmirriahi, Rezaei A, Oresi A

Elevated levels of methylglyoxal may contribute to the development of thrombotic complications in diabetes mellitus
Léránt I*, Kolev K, Machovich R

Plasma flow velocity and fibrin specificity of thrombolytic agent promote thrombolysis of non-retracted and retracted whole blood clots
Tratar G*, Blinc A, Štrukelj M, Mikac U, Šerša I

Coagulation/fibrinolysis system parameters are affected by smoking cessation

Plasminogen Activator Inhibitor (PAI) 4G/5G polymorphism in patients with coronary artery disease

The relationship between Ins/Del (I/D) polymorphism in ACE gene with t-PA I/D and PAI-1 4G/5G polymorphisms in PE
Altinok B*, Öner F, Numanoglu N, Oguzulgen K, Ekim N, Akar N

PAI-1 levels, 4G/5G genotype and insulin resistance in severe and morbid obesity. Effect of weight loss and influence of 4G/5G genotype

Haemostasis activation markers

Poster withdrawn

Troponin concentration in NSTEMI patients depends on intensity of prothrombotic reactions

D-dimer and soluble fibrin at ischemic heart disease and acute impairment cerebral circulation
Lugovskoy E*, Kolesnikova I, Gritsenko P, Lugovskaya N, Komisarenko S

D-dimer levels in long term anticoagulated patients
Gafou A*, Tsevrenis V, Nomikou E, Bellia M, Paulou E, Andrioti E

A normal Wells’s score and a normal D-dimer test safely exclude pulmonary embolism
Söderberg M*, Brohult J

D- diagnosis in pulmonary embolism
Škrgat-Kristan S*, Meško Bruguían P*, Košnik M, Šorli J

The usefulness of D-dimer in hospitalized patients with lung diseases

The characteristic of the soluble fibrin-monomer complexes fraction
Savchuk O*, Volodymyr C, Tatyana P

Management of coagulopathy and associated severe bleeding in immediate post-partum period
Gonçalves L*, Oliveira G, Pereira R, Cunha-Ribeiro L

Increased thrombin-antithrombin III levels in preeclampsia and disseminated intravascular coagulation on two different ELISAs
Simpson D, Whittier A, Andrews J, Fink C, Lopez L

Heparins and related drugs

Effect of parnaparin, a low molecular weight heparin, on platelet-leukocyte interaction
Maugeri N*, de Gaetano G, Donati MB, Cerletti C

Paradoxical action of the synthetic pentasaccharide (Arixtra®)

Influence of the original low molecular weight heparin on the rabbits plasma anticoagulant activity
Drozd N*, Bannicova G, Sukhanova P, Miphtakhova N, Makarov V, Varlamov V, Vihoreva G

Different response of bone turnover markers during venous thromboembolic prophylaxis with LMWH or oral anticoagulants
Wawrzynska L*, Przedlacki J, Hajduk B, Tomkowski W, Torbicki A
The aPTT paradox of the bridging process
Volteas S*, Bossinakou I, parigoti A, Kalatzopoulos D, Matheou S, Nikolakeas M, Sikiotos K

Pharmacoeconomic analysis of heparin vs. enoxaparin as prophylaxis for venous thromboembolism in total knee replacement surgery
Honorato J, Gómez-Outes A*, Navarro-Quilis A, Martinez-González J*, Rocha E, Planès A

Comparative profile of tinzaparin and a sulfaminoheparosan of bacterial origin: a possible potential alternate for low molecular weight heparins
Maddineni J*, Manoni M, Cornelli U, Hoppensteadt D, Fareed J

Partial results of the incidence of heparin induced thrombocytopenia
Oliveira S, Rached R*, Cavalheiro-Filho C, Chamone D

Confirmation of the pathogenic role of Ig M and Ig A anti-heparin-PF4 antibodies in patients with heparin-induced thrombocytopenia
Tardy-Poncet B*, Tardy B, Piot M, Reynaud J, Campos L, Decousus H

Inflammation

Plasma pro and anticoagulant factors in the early stages of Buerger’s disease

Oxidative stress, cardiovascular disease and CC-chemokine levels in haemodialyzed patients
Pawlak D*, Pawlak K, Myśliwiec M

Possible vascular-bed-specific role of interleukin-6 in young women with a history of three different types of thrombosis
Salobir B*, Sabovič M

Haemostatic abnormalities and inflammatory cytokines in patients with chronic obstructive pulmonary disease
Ferroni P*, Martini F, Guadagni F, Roselli M, Bertazzoni G, Basili S

Inflammatory markers and C-IMT in patients with previous myocardial infarction. The atorvastatin effect. MIAMI Study
Cortellaro M*, Tremoli E on behalf of the MIAMI Study Group

Haemodialysis patients have more prominent non-classical than classical cardiovascular risk factors
Vujkovac B*, Lavre J, Šabovič M

The most important factor for cardiovascular morbidity in haemodialysis patients is microinflammation
Lavré J*, Vujkovac B, Šabovič M

Lupus anticoagulants

Circulating plasma levels of annexin V in venous thromboembolism (VTE)
González-Ordóñez A*, Macías D, Arias A, Ramas C, del Blanco JM, Morán M

Lupus ratio (LR) and correction ratio (CR) applying to dRVVT results
Gennari L, Blanco A*, Grosso S, Dominguez M, Lazzari M

Antiphospholipid antibodies in young women without autoimmune diseases and suffering from arterial or venous thromboses
Salobir B*, Šabovič M, Hojnik M, Kučnik S, Kveder T

Autoantibodies to B2GPI/OxLDL complexes: a novel risk factor for thromboembolic disease in systemic lupus erythematosus?
Lopez L*, Garcia De La Torre J, Matsuura E

Protein C inhibitor, isolated together with β2-glycoprotein I (β2GPI). A possible player in anti-β2GPI antibody mediated thrombosis?
Kučnik S*, Rozman B, Kveder T, Božič B

Thrombosis risk in systemic lupus erythematosus
Sallai K*, Nagy E, Gergely P, Bodó I

Management of pregnancy in patients with autoimmune diseases and antiphospholipid syndrome
Makatsaria A*, Muravieva I, Kusainova V

Prediction value of several functional examinations for the identification of antiphospholipid-antibody syndrome
Pecka M*, Maly J, Slezkova E, Dulicek P

Antiphospholipid antibodies enclosed to diagnosis of venous thrombosis
Kostovska S, Neceva V*, Pockova L, Pejceva J, Dejanova V

Methods in coagulation

Thrombin concentration and clotting time
Savushkin AV

The comparison of clotting and colorimetric assay of quantitative measurement of the functional protein C level
Slezakova E*, Pecka M, Maly J

Effect of platelet factor 4 on laboratory tests of the protein C system
Van Dreden P*, Rousseau A, Woodhams B

Influence of fibrin polymerization on citrated whole blood thromboelastography profile
Chakroun T, Gerotziafas, Samama M, Elalamy I*
Is the Light Cycler- real time PCR as reliable as the conventional PCR? Our experience
Saour T, Sheereen A, Saour B, Saour J, Mammo L
PO139

Evaluation of the Dialab APC Sensitivity Assay
Coen D*, Milos M, Zadro R
PO140

A practical von Willebrand disease screening method using ELISAs
Whittier A*, Andrews J, Fink C, Lopez L
PO141

Perinatal and paediatric haemostasis

Iliofemoral deep vein thrombosis in childhood; developing a management protocol
Brightwell R*, Osman I
PO142

Prothrombin gene 20210 GÆA heterozygote mutation in a patient with multiple thrombosis - a case report
Ileri T*, Uysal Z, Azik F, Ertem M, Akar N, Kologlu M, Dindar H, Gozdasoglu S
PO143

Study of haemostasis in neonates with intrauterine growth retardation (IUGR)
PO144

Is long term prophylaxis in pediatric stroke necessary?
Unal O, Uysal Z, Ocal G, Akar N, Deda G*
PO145

Cervical artery dissection: long term outcome after anticoagulant therapy
Quintavalla R*, Paganelli E, Pattacini C, Rossetti A
PO146

Homocysteine in pediatric patients with migraine
Katsadze Y*, Tadaeva Z, Shmeleva V
PO147

Frequency and association between polymorphism MTHFR gene, folic acid, vitamin B12 and mild hyperhomo-cysteinemia in pediatric stroke
PO148

The role of cathpsin G (N125S) and TNF-(-308G/A) polymorphisms in the Turkish pediatric cerebrovascular attack (CVA) patients
Hasipek M*, Karahan Z, Deda G, Akar E, Akar N
PO149

Homoyzgous factor V G1691A mutation in Turkish children with thrombosis
Ulu A, Yildiz Z, Akar E*, Akar N
PO150

Prothrombin G20210A and A19911G in Turkish pediatric stroke patients
Yildiz Z*, Akar N, Deda G
PO151

Successful immune tolerance therapy with vWF/FVIII concentrate in a hemophilic child with inhibitor
Unuvar A*, Saribeyoglu E, Anak S, Devecioglu O
PO152

Alterations of coagulation pathway parameters in children with sickle cell disease (SCD)
PO153

The role of inherited hypercoagulable abnormalities in pediatric hematopoietic stem cell transplantation
Ertem M*, Azik F, Ileri T, Akar E, Ulu A, Akar N
PO154

Importance of HDL-Cholesterol determination for the diagnosis of hypercholesterolemia during childhood
PO155

Thrombogenic parameters in hypercholesterolemic children
PO156

TFPI -33T→C polymorphism in Turkish children with cerebreal infarct
Donmez BN*, Deda G, Sipahi T, Çaksen H, Cin Ş, Akar N
PO157

Body mass index and atherothrombotic risk factors during childhood
PO158

FXIII Val34Leu gene polymorphism in Turkish children with cerebral infarct
Donmez BN*, Deda G, Akar N
PO159

Deficiency of coagulation inhibitors in children with ischemic stroke and transient ischemic attack (TIA)
Lenicek Krleza J*, Coen D, Zadro R, Studljenic-Rukavina A
PO160

Thromboembolic complication in children with oncologic disease - review of two cases
Vukelic-Damijani N*, Smokvina M, Caser L, Vujaklija-Stipanovic K
PO161

Platelets

Normal ranges with PFA-100 (Dade-Behring) in healthy subjects
PO162

Function of platelets: comparison of findings between the PFA-100 and the aggregometer in normal subjects
Makris P*, Boutou A, Sarridou D, Papamichos S, Tsoukas D, Bougiouklis D, Zarkakopoulos A, Papageorgiou I, Anastakis D, Girtovitis F
PO163

PADA - Fast and quantitative monitoring of blood platelet adhesiveness
Nowak G*, Bucha E, Wiesenburg A, Schumann A
PO164
<table>
<thead>
<tr>
<th>Title</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poly-APS induced thromocyte aggregation is partly blocked by the combination of acetylsalicylic acid, clopidogrel and abciximab</td>
<td>PO165</td>
</tr>
<tr>
<td>Influence of platelet activation agonists on lymphocyte-platelet adhesion</td>
<td>PO166</td>
</tr>
<tr>
<td>Influence of recombinant interleukin 2 on platelet aggregation and lymphocyte-platelet adhesion</td>
<td>PO167</td>
</tr>
<tr>
<td>The severity of peripheral arterial disease can influence plasma platelet microparticle levels</td>
<td>PO168</td>
</tr>
<tr>
<td>Patients with stable ischaemic heart disease have increased levels of platelet microparticles</td>
<td>PO169</td>
</tr>
<tr>
<td>Prevalence of aspirin resistance in cardiovascular patients using the PFA-100 diagnostic system</td>
<td>PO170</td>
</tr>
<tr>
<td>Clinical effects of combined tirofiban with LMWH in patients with acute coronary syndrome</td>
<td>PO171</td>
</tr>
<tr>
<td>Thrombocytopenia in the intensive care unit. Case series</td>
<td>PO172</td>
</tr>
<tr>
<td>Salvage plasmapheresis in case of pulmonary embolism caused by heparin-induced thrombocytopenia type II resistant to danaparoid sodium and lepirudin</td>
<td>PO173</td>
</tr>
<tr>
<td>Prospective study of coagulability in pregnancy - a new approach to the early detection of preeclampsia and cardiovascular complications</td>
<td>PO174</td>
</tr>
<tr>
<td>No need for laboratory monitoring during low dose LMMH thromboprophylaxis during pregnancy</td>
<td>PO175</td>
</tr>
<tr>
<td>Factor VIII levels in the early postpartum period</td>
<td>PO176</td>
</tr>
<tr>
<td>Polymorphism of gene PAI-1 4G/4G and preemembionic losses</td>
<td>PO177</td>
</tr>
<tr>
<td>Acute vascular violations in pregnant women with thrombophilias</td>
<td>PO178</td>
</tr>
<tr>
<td>The effects of oral hormone replacement therapy on C-reactive protein and other inflammatory markers in women with previous venous thromboembolism</td>
<td>PO179</td>
</tr>
<tr>
<td>Estrogen receptors and venous thrombosis</td>
<td>PO180</td>
</tr>
<tr>
<td>The effect of norethisterone acetate on inflammatory markers in postmenopausal women receiving estradiol</td>
<td>PO181</td>
</tr>
<tr>
<td>The influence of hormone replacement therapy (HRT) on factor VIIa/antithrombin (FVIIa/AT) complex</td>
<td>PO182</td>
</tr>
<tr>
<td>Thrombophilic mutations as inherited risk factors for myocardial infarction in postmenopausal women</td>
<td>PO183</td>
</tr>
<tr>
<td>Thrombophilia</td>
<td>PO184</td>
</tr>
<tr>
<td>Venous thrombosis and pulmonary embolism in a woman with breast cancer</td>
<td>PO185</td>
</tr>
<tr>
<td>Coagulation studies in patients with thrombosed prosthetic heart valves and intracardiac clots</td>
<td>PO186</td>
</tr>
<tr>
<td>Thrombosis and familial thrombophilia registry, preliminary report</td>
<td>PO187</td>
</tr>
<tr>
<td>Frequency of hereditary thrombophilia in Egypt population</td>
<td>PO188</td>
</tr>
<tr>
<td>Prothrombin G20210A mutation in patients with cerebrovascular disease</td>
<td>PO189</td>
</tr>
<tr>
<td>Prothrombin G20210 mutation and association with severe life threatening thrombosis among thrombophilic patients</td>
<td>PO190</td>
</tr>
</tbody>
</table>
Thrombosis associated with multiple hereditary prothrombotic risk factors and sepsis

Thrombophilia markers in venous thrombotic events
Canak V, Povazan L, Mitic G, Gnep S, Latinovic O

Case report of a family with inherited combinator deficiency of protein C and antithrombin III
Trajkov A, Kostovska S*, Neceva V*, Pejceva J, Dimovska N

Combined congenital thrombophilia and essential thrombocytopenia in patients with recidivous pulmonary embolisms and myocardial infarction

The role of PT 20210 G-A, FVL 1691 G-A and FV 4070 A-G as thrombotic risk factors in the development of idiopathic sudden hearing loss
Yildiz Z*, Incesulu A, Oztapan Y, Akar N, Tekin M

Factor V Leiden mutation and blood coagulation at the site of microvascular injury in healthy and anticoagulated subjects
Undas A*, Brzezinska-Kolarz B, Iwaniec T, Brozek J, Musial J

**VTE**

Effects of enoxaparine for prevention of thrombosis and thromboembolias in patients with chronic heart failure
Olbinskaya L, Kochkareva J, Kolossova K

Multicentric, observational, cross-sectional study to evaluate the VTE risk factors and venous thromboprophylaxis use: a pilot study

Thrombotic complications of peripherally inserted central catheters: a one year retrospective study
Perron S*, Miron M

True incidence of arterial and venous thromboembolic events in the THA patient?
Ryge C*, Rud Lassen M, Solgaard S, Sonne Holm S, Boris L

Epidemiology of post-operative venous thromboembolism in Asian countries: preliminary results of the SMART venography study
Leizorovicz A*, Study Group t

Thrombolytic therapy in patients with phlegmasia cerulea dolens
Tardy B*, Moulin N, Mismetti P, Decousus H, Laporte S

Management of thrombophlebitis with two-layer short-stretch bandages
Planinshek Ruçigaj T*, Košiček M

Haemorheological and haemostatic alterations in patients with Idiopathic Sudden Sensorineural Hearing Loss

Thrombotic complication treated with defibrotide followed by central nervous system failure in a child after bone marrow transplantation
Dobaczewski G*, Latos-Grazynska E, Wrobel G, Szmyd K, Chybicka A, Toporski J

Residual venous obstruction in patients with a single episode of deep vein thrombosis (DVT) and in patients with recurrent DVT
Dentali F*, Ageno W, Galli M, Mera V, Manfredi E, Steidl L, Venco A

Hydrofibre dressing versus ointments in the treatment of venous leg ulcers
Košiček M*, Planinshek Ruçigaj T

The floating thrombus: a fictitious actor on thromboembolic set (considerations about a clinical case)
Lo Pinto G*

The influence of advanced age and immobility on physician practices for prescribing venous thromboembolism prophylaxis to medical patients
Decousus H*, Tapson V, Chong B, Merli G, Kakkar A, FitzGerald G

Prevention of venous thromboembolism: evaluation of the use of thromboprophylaxis guidelines in a teaching hospital
Grand B*, Duarte P*, Orosco J, Gutierrez R, Oscar M, Riveros D*

Evaluation of the symptoms of acute venous thromboembolism
Racchi R*, De Piano L, Cavalheiro C, Chamone D

Progressive versus decreasing elastic stockings in patients presenting with mild venous insufficiency: a randomised clinical trial
Couzan S, Assante C, Pouget J, Pruner M, Laporte S, Mismetti P*

Pathophysiol Haemost Thromb 2003; 33 (suppl2)  XXIII